Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813717 | 0.91 | HRH3 (0.70) | HRH3HPGDL3MBTL3L3MBTL1 | |
| SCHEMBL1814276 | 0.91 | HRH3 (0.70) | HRH3HPGDL3MBTL3L3MBTL1 | |
| SCHEMBL1811662 | 0.90 | HRH3 (0.59) | HRH3FGFR1HPGDL3MBTL3L3MBTL1 | |
| SCHEMBL1816825 | 0.90 | HRH3 (0.59) | HRH3FGFR1HPGDL3MBTL3L3MBTL1 | |
| SCHEMBL1811901 | 0.90 | HRH3 (0.69) | HRH3HPGDL3MBTL3L3MBTL1 | |
| SCHEMBL1810015 | 0.90 | HRH3 (0.69) | HRH3HPGDL3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1811397 | 0.90 | HRH3 (0.69) | HRH3HPGDL3MBTL3L3MBTL1 | |
| SCHEMBL4941303 | 0.85 | HPGD (0.59) | HRH3FGFR1HPGD | |
| SCHEMBL1815151 | 0.84 | HRH3 (0.52) | HRH3FGFR1HPGD | |
| SCHEMBL1816245 | 0.84 | HRH3 (0.52) | HRH3FGFR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | claimed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | claimed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | HRH3 3/4885FGFR1 2424/4885HPGD 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.